Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
DEA proposes temporary Schedule I placement for 7-hydroxymitragynine above a specified threshold. This substance is not commonly used in cosmetics, but any product containing it (e.g., in personal care items) would become illegal. Immediate review of ingredient lists is required.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon publication of the temporary order (expected soon).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
7-hydroxymitragynine above a specified threshold is temporarily placed in Schedule I, making it illegal to possess, distribute, or manufacture.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors
What you must do
Verify that no products contain 7-hydroxymitragynine above the threshold. If any do, cease production and distribution immediately.
Deadline
Effective upon publication of the temporary order (expected soon).
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection